Management of Alcohol Withdrawal Syndrome

Initial Assessment and Risk Stratification

The American College of Physicians recommends using the CIWA-Ar score to guide treatment intensity, with scores >8 indicating moderate AWS requiring treatment, and scores ≥15 indicating severe AWS requiring aggressive management 1, 3

The American Academy of Family Physicians suggests that benzodiazepines are the gold standard first-line treatment for alcohol withdrawal syndrome, with long-acting agents like diazepam and chlordiazepoxide preferred for most patients to prevent seizures and delirium tremens 1, 2, 3
For patients with advanced age, hepatic dysfunction, liver failure, respiratory failure, obesity, or recent head trauma, the American College of Clinical Pharmacology recommends switching to lorazepam 1, 2, 3
The American Society of Addiction Medicine recommends lorazepam dosing of 1-4 mg every 4-8 hours, then tapering after symptom resolution 1, 3
The National Institute on Alcohol Abuse and Alcoholism suggests that thiamine 100-300 mg/day must be administered to all patients with alcohol withdrawal to prevent Wernicke encephalopathy 1, 2, 3
The American College of Emergency Physicians recommends giving thiamine before any glucose-containing IV fluids to prevent precipitating acute thiamine deficiency 1, 3

The American Academy of Neurology recommends carbamazepine 200 mg every 6-8 hours as an alternative for seizure prevention 1, 2, 3
The American Psychiatric Association suggests haloperidol 0.5-5 mg every 8-12 hours as adjunctive therapy for agitation or psychotic symptoms not controlled by benzodiazepines alone 1, 2, 3

The American Society of Addiction Medicine recommends tapering benzodiazepines following resolution of withdrawal symptoms, with total treatment duration not exceeding 10-14 days to avoid benzodiazepine dependence 1, 3

The American College of Physicians recommends admitting patients to inpatient treatment for serious medical complications, high levels of recent drinking, history of withdrawal seizures or delirium tremens, or co-occurring serious medical or psychiatric illness 1, 2, 3

The European Association for the Study of the Liver recommends avoiding disulfiram and naltrexone in patients with alcoholic liver disease due to the risk of hepatotoxicity 4, 2, 3

The American College of Physicians recommends psychiatric consultation for comprehensive evaluation, acute AWS management, and long-term abstinence planning 1
The American Association for the Study of Liver Diseases suggests coordinating care between hepatologists and addiction specialists to reduce delays in referral for alcohol dependence treatment 4